Rucaparib: all 54 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• CATCH-R: A Rollover Study to Provide Continued Access to RucaparibCompletedNCT04676334Phase 3Results posted
• A Study of Rucaparib and Nivolumab in People With LeiomyosarcomaActive, not recruitingNCT04624178Phase 2Results posted
• PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell CancersCompletedNCT04209595Phase 1/2Results posted
• A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR GenesTerminatedNCT04171700Phase 2Results posted
• Combination Rucaparib With Nivolumab in Small Cell Lung CarcinomaCompletedNCT03958045Phase 2Results posted
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)CompletedNCT03845296Phase 2Results posted
• A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.CompletedNCT03840200Phase 1Results posted
• A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)TerminatedNCT03824704Phase 2Results posted
• The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)CompletedNCT03694262Phase 2Results posted
• Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedNCT03654833Phase 2Results posted
• Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyCompletedNCT03639935Phase 2Results posted
• Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial CancerCompletedNCT03617679Phase 2Results posted
• Rucaparib and Nivolumab in Patients With Prostate or Endometrial CancerTerminatedNCT03572478Phase 1/2Results posted
• Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerTerminatedNCT03559049Phase 1/2Results posted
• A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following ChemotherapyCompletedNCT03542175Phase 1Results posted
• Rucaparib in Nonmetastatic prOstAte With BRCAnessTerminatedNCT03533946Phase 2Results posted
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based ChemotherapyActive, not recruitingNCT03522246Phase 3Results posted
• Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or EndometriumCompletedNCT03476798Phase 2Results posted
• Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair DeficiencyTerminatedNCT03442556Phase 2Results posted
• Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene MutationsCompletedNCT03413995Phase 2Results posted
• Rucaparib in Patients With Locally Advanced or Metastatic Urothelial CarcinomaTerminatedNCT03397394Phase 2Results posted
• An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerCompletedNCT03338790Phase 2Results posted
• Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary CancerActive, not recruitingNCT03337087Phase 1/2Results posted
• Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based TherapyTerminatedNCT03140670Phase 2Results posted
• A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedNCT02975934Phase 3Results posted
• A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedNCT02952534Phase 2Results posted
• A Study to Test Combination Treatments in Participants With Advanced Gastric CancerCompletedNCT02935634Phase 2Results posted
• A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibActive, not recruitingNCT02873962Phase 2Results posted
• ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsCompletedNCT02855944Phase 3Results posted
• Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)CompletedNCT01968213Phase 3Results posted
• A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)CompletedNCT01891344Phase 2Results posted
• A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)CompletedNCT01482715Phase 1/2Results posted
• PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 MutationsCompletedNCT01074970Phase 2Results posted
• Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid TumorsTerminatedNCT04276376Phase 2
• A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT04253262Phase 1/2
• Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer PatientsCompletedNCT04227522Phase 3
• Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral ContraceptivesCompletedNCT03954366Phase 1
• Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast TumorsCompletedNCT03911453Early Phase 1
• Rucaparib Maintenance Therapy in Advanced Cervical CancerWithdrawnNCT03795272Phase 2
• Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT03552471Phase 1
• Rucaparib Hepatic Impairment Study in Patients With a Solid TumorCompletedNCT03521037Phase 1
• A Study of Rucaparib in Japanese Patients With a Previously-treated Solid TumorCompletedNCT03499444Phase 1
• Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva CombinationStatus unknownNCT03462212Phase 1/2
• A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast CancerCompletedNCT03101280Phase 1
• Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-RucaparibCompletedNCT02986100Phase 1
• Pharmacokinetic Drug-Drug Interaction Study of RucaparibCompletedNCT02740712Phase 1
• Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialActive, not recruitingNCT02678182Phase 2
• A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic SignatureCompletedNCT02505048Phase 2
• A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA MutationCompletedNCT02042378Phase 2
• A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic RegimensCompletedNCT01009190Phase 1
• Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian CancerCompletedNCT00664781Phase 2
• A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)WithdrawnNCT00457470Phase 2

← Rucaparib overview